Biotech Industry Examiner

Menu
Menu
subscribe now
Search
From Platform to Precision: The $800M Bet Transforming Biotech Investing

From Platform to Precision: The $800M Bet Transforming Biotech Investing

Inside TCG Labs Soleil’s $400M Bet on Focused Biotech On

Illumina’s Market Struggles Deepen as U.S.-China Tensions Escalate

Illumina’s Market Struggles Deepen as U.S.-China Tensions Escalate

Illumina, a prominent biotech firm specializing in gene-sequencing technology, is

Illumina Faces Potential $7 Billion Loss from Forced Grail Sale: An Analysis

Illumina Faces Potential $7 Billion Loss from Forced Grail Sale: An Analysis

1. Introduction Background on Illumina and Grail Illumina, Inc. is

EU Sets New Goals for Advancing Biotechnology and Biomanufacturing

EU Sets New Goals for Advancing Biotechnology and Biomanufacturing

job louana237 Executive Summary The EU Biotech and Biomanufacturing Initiative

AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments

AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments

1. Introduction BioXcel Therapeutics is a biopharmaceutical company leveraging artificial

Biogen’s $5.6 Billion Apellis Deal Is Really a Bet on Kidney Disease

Biogen’s $5.6 Billion Apellis Deal Is Really a Bet on Kidney Disease

Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda

Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda

Biotech’s AI Race Is No Longer About Models. It’s About Infrastructure.

Biotech’s AI Race Is No Longer About Models. It’s About Infrastructure.

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing

MOST POPULAR

News

The FDA wants to “pre-check” factories before the medicine exists
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Biogen’s $5.6 Billion Apellis Deal Is Really a Bet on Kidney Disease
Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda
Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation
Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top